The Impact of PSMA PET-CT on Treatment Decisions in Prostate Cancer – Early Experience in a Single Centre

Purpose: Relapsed or progressive prostate cancer frequently manifests as consecutive PSA rises long before disease is clinically detectable. Imaging with novel radiotracers targeting prostate-specific membrane antigen (PSMA) has been shown to be more sensitive in identifying the site of disease at lower PSA levels compared with conventional imaging, which may provide increased opportunity for salvage therapy, more aggressive local management of oligometastatic disease or increased confidence in proceeding with systemic therapy [1].
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research

Related Links:

Conditions:   Prostate Cancer;   Radical Prostatectomy Intervention:   Combination Product: Microdevice Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8 Interventions:   Radiation: High-Dose Rate Brachytherapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Rad...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 24 May 2020Source: European UrologyAuthor(s): Amar U. Kishan, Tahmineh Romero, Mohammed Alshalalfa, Yang Liu, Phuoc T. Tran, Nicholas G. Nickols, Huihui Ye, Dipti Sajed, Matthew B. Rettig, Robert E. Reiter, Isla P. Garraway, Daniel E. Spratt, Steven J. Freedland, Xin Zhao, Ziwen Li, Matthew Deek, Julie Livingstone, Brandon A. Mahal, Paul L. Nguyen, Felix Y. Feng
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conditions:   Prostate Cancer;   Radical Prostatectomy Intervention:   Combination Product: Microdevice Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8 Interventions:   Radiation: High-Dose Rate Brachytherapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Rad...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Despite the emphasis on randomized data to guide evidence-based practice, there is a notable lack of clinical trials to inform comparative effectiveness in surgical disciplines. Although this is multifactorial in nature, this paucity ultimately reflects the difficulty associated with conducting surgical trials, particularly in settings where event rates are low (eg, lymph node metastasis in M0 renal cell carcinoma) or when long follow-up is required, as with early-stage disease (eg, low-risk prostate cancer).
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2 –3 years. A subgroup of those patients with mC...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Study protocol Source Type: research
o-Hong Chen Enzalutamide is the first second-generation nonsteroidal androgen receptor (AR) antagonist with a strong binding affinity to AR. Most significantly, enzalutamide can prolong not only overall survival time and metastatic free survival time for patients with lethal castration-resistant prostate cancer (CRPC), but also castration-resistant free survival time for patients with castration-sensitive prostate cancer (CSPC). Enzalutamide has thus been approved by the US Food and Drug Administration (FDA) for the treatment of both metastatic (in 2012) and non-metastatic (in 2018) CRPC, as well as CSPC (2019). This i...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
Publication date: Available online 22 May 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Giandomenico Roviello, Benedetta Panella
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 22 May 2020Source: European UrologyAuthor(s): Steven M. Monda, Marc Arnaldo Dall’Era
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Prostate Cancer | Radiology